CN110357891B - Chromone-substituted 2-hydroxypyrrole derivative and synthesis method and application thereof - Google Patents
Chromone-substituted 2-hydroxypyrrole derivative and synthesis method and application thereof Download PDFInfo
- Publication number
- CN110357891B CN110357891B CN201910602021.3A CN201910602021A CN110357891B CN 110357891 B CN110357891 B CN 110357891B CN 201910602021 A CN201910602021 A CN 201910602021A CN 110357891 B CN110357891 B CN 110357891B
- Authority
- CN
- China
- Prior art keywords
- derivative
- ylidene
- hydroxy
- chromone
- hydroxypyrrole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WLODWTPNUWYZKN-UHFFFAOYSA-N 1h-pyrrol-2-ol Chemical class OC1=CC=CN1 WLODWTPNUWYZKN-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 238000001308 synthesis method Methods 0.000 title abstract description 28
- -1 p-methylbenzoyl Chemical group 0.000 claims abstract description 126
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims abstract description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 36
- 239000001257 hydrogen Substances 0.000 claims abstract description 36
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical class O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 claims abstract description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 19
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000011737 fluorine Chemical group 0.000 claims abstract description 15
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 13
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 claims abstract description 12
- 239000000460 chlorine Chemical group 0.000 claims abstract description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 10
- CFNMUZCFSDMZPQ-GHXNOFRVSA-N 7-[(z)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC/C=C(/C)CC1OC(=O)C(C)=C1 CFNMUZCFSDMZPQ-GHXNOFRVSA-N 0.000 claims abstract description 9
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 144
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 100
- 239000002904 solvent Substances 0.000 claims description 51
- 239000003208 petroleum Substances 0.000 claims description 50
- 238000004440 column chromatography Methods 0.000 claims description 45
- 239000012295 chemical reaction liquid Substances 0.000 claims description 42
- 239000012046 mixed solvent Substances 0.000 claims description 31
- 238000001816 cooling Methods 0.000 claims description 23
- 239000003480 eluent Substances 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 23
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000013375 chromatographic separation Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 50
- 150000001875 compounds Chemical class 0.000 abstract description 32
- 239000002994 raw material Substances 0.000 abstract description 25
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 11
- 238000005580 one pot reaction Methods 0.000 abstract description 4
- BQLSCAPEANVCOG-UHFFFAOYSA-N chromene-2,4-dione Chemical compound C1=CC=C2OC(=O)CC(=O)C2=C1 BQLSCAPEANVCOG-UHFFFAOYSA-N 0.000 description 57
- VXIXUWQIVKSKSA-UHFFFAOYSA-N 4-hydroxycoumarin Chemical compound C1=CC=CC2=C1OC(=O)C=C2O VXIXUWQIVKSKSA-UHFFFAOYSA-N 0.000 description 46
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 40
- 238000005481 NMR spectroscopy Methods 0.000 description 31
- YQBLQKZERMAVDO-UHFFFAOYSA-N 2-oxo-2-phenylacetaldehyde;hydrate Chemical compound O.O=CC(=O)C1=CC=CC=C1 YQBLQKZERMAVDO-UHFFFAOYSA-N 0.000 description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 22
- 229910052799 carbon Inorganic materials 0.000 description 22
- 238000004809 thin layer chromatography Methods 0.000 description 22
- 238000001819 mass spectrum Methods 0.000 description 21
- 238000002844 melting Methods 0.000 description 18
- 230000008018 melting Effects 0.000 description 18
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 16
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 14
- 238000004611 spectroscopical analysis Methods 0.000 description 13
- 238000001228 spectrum Methods 0.000 description 13
- 238000010992 reflux Methods 0.000 description 12
- HUMZENGQNOATEQ-UHFFFAOYSA-N 6-chloro-4-hydroxycoumarin Chemical compound C1=CC(Cl)=CC2=C1OC(=O)C=C2O HUMZENGQNOATEQ-UHFFFAOYSA-N 0.000 description 10
- FFYIMFMDGMXVOF-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-2-oxoacetaldehyde;hydrate Chemical compound O.FC1=CC=C(C(=O)C=O)C=C1F FFYIMFMDGMXVOF-UHFFFAOYSA-N 0.000 description 9
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 8
- NKCHIVNVVWNVFN-OCOZRVBESA-N C(C1=CC=CC=C1)(=O)C=1/C(/C(N2C=1NCCC2)(C1=CC=C(C=C1)C)O)=C/1\C(OC2=CC=C(C=C2C\1=O)Cl)=O Chemical compound C(C1=CC=CC=C1)(=O)C=1/C(/C(N2C=1NCCC2)(C1=CC=C(C=C1)C)O)=C/1\C(OC2=CC=C(C=C2C\1=O)Cl)=O NKCHIVNVVWNVFN-OCOZRVBESA-N 0.000 description 7
- PWNDBEVZUPRDCU-OCEACIFDSA-N ClC1=CC=C(C(=O)C=2/C(/C(N3C=2NCCC3)(C2=CC=C(C=C2)C)O)=C/2\C(OC3=CC=C(C=C3C\2=O)C)=O)C=C1 Chemical compound ClC1=CC=C(C(=O)C=2/C(/C(N3C=2NCCC3)(C2=CC=C(C=C2)C)O)=C/2\C(OC3=CC=C(C=C3C\2=O)C)=O)C=C1 PWNDBEVZUPRDCU-OCEACIFDSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- JZJXSEZCPBRRLU-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-oxoacetaldehyde;hydrate Chemical compound O.FC1=CC=C(C(=O)C=O)C=C1 JZJXSEZCPBRRLU-UHFFFAOYSA-N 0.000 description 6
- WIRGBZBGYNIZIB-UHFFFAOYSA-N 4-hydroxy-6-methylchromen-2-one Chemical compound O1C(=O)C=C(O)C2=CC(C)=CC=C21 WIRGBZBGYNIZIB-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- QAZIOCWEZXPEFM-OCEACIFDSA-N C(C1=CC=CC=C1)(=O)C=1/C(/C(N2C=1NCCC2)(C1=CC=C(C=C1)C)O)=C/1\C(OC2=CC=C(C=C2C\1=O)C)=O Chemical compound C(C1=CC=CC=C1)(=O)C=1/C(/C(N2C=1NCCC2)(C1=CC=C(C=C1)C)O)=C/1\C(OC2=CC=C(C=C2C\1=O)C)=O QAZIOCWEZXPEFM-OCEACIFDSA-N 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- QGRQCFXTNVRQCI-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-imidazolidin-2-ylideneethanone Chemical compound C1=CC(Cl)=CC=C1C(=O)C=C1NCCN1 QGRQCFXTNVRQCI-UHFFFAOYSA-N 0.000 description 4
- CLRJDSNOHLWHGU-UHFFFAOYSA-N 2-(1,3-diazinan-2-ylidene)-1-(4-methylphenyl)ethanone Chemical compound C1=CC(C)=CC=C1C(=O)C=C1NCCCN1 CLRJDSNOHLWHGU-UHFFFAOYSA-N 0.000 description 4
- AUQWARJGSITBAN-UHFFFAOYSA-N 2-(1,3-diazinan-2-ylidene)-1-phenylethanone Chemical compound C=1C=CC=CC=1C(=O)C=C1NCCCN1 AUQWARJGSITBAN-UHFFFAOYSA-N 0.000 description 4
- FBRSGILTGRDGFN-OCOZRVBESA-N BrC=1C=C2C(\C(\C(OC2=CC=1)=O)=C/1\C(=C2N(CCCN2)C\1(C1=CC=CC=C1)O)C(C1=CC=C(C=C1)C)=O)=O Chemical compound BrC=1C=C2C(\C(\C(OC2=CC=1)=O)=C/1\C(=C2N(CCCN2)C\1(C1=CC=CC=C1)O)C(C1=CC=C(C=C1)C)=O)=O FBRSGILTGRDGFN-OCOZRVBESA-N 0.000 description 4
- QALHWCJZTIVQFJ-WCWDXBQESA-N C(C1=CC=CC=C1)(=O)C=1/C(/C(N2C=1NCCC2)(C1=CC=CC=C1)O)=C/1\C(OC2=CC=CC=C2C\1=O)=O Chemical compound C(C1=CC=CC=C1)(=O)C=1/C(/C(N2C=1NCCC2)(C1=CC=CC=C1)O)=C/1\C(OC2=CC=CC=C2C\1=O)=O QALHWCJZTIVQFJ-WCWDXBQESA-N 0.000 description 4
- RBGPMBZFNCNGOZ-WCWDXBQESA-N ClC=1C=C2C(\C(\C(OC2=CC=1)=O)=C/1\C(=C2N(CCCN2)C\1(C1=CC=CC=C1)O)C(C1=CC=C(C=C1)Cl)=O)=O Chemical compound ClC=1C=C2C(\C(\C(OC2=CC=1)=O)=C/1\C(=C2N(CCCN2)C\1(C1=CC=CC=C1)O)C(C1=CC=C(C=C1)Cl)=O)=O RBGPMBZFNCNGOZ-WCWDXBQESA-N 0.000 description 4
- 239000005977 Ethylene Substances 0.000 description 4
- HQFMBEJLVCLNFT-OCOZRVBESA-N FC1=CC=C(C(=O)C=2/C(/C(N3C=2NCCC3)(C2=CC=C(C=C2)C)O)=C/2\C(OC3=CC=CC=C3C\2=O)=O)C=C1 Chemical compound FC1=CC=C(C(=O)C=2/C(/C(N3C=2NCCC3)(C2=CC=C(C=C2)C)O)=C/2\C(OC3=CC=CC=C3C\2=O)=O)C=C1 HQFMBEJLVCLNFT-OCOZRVBESA-N 0.000 description 4
- YOGHDWYPXHDDHW-WCWDXBQESA-N FC1=CC=C(C(=O)C=2/C(/C(N3C=2NCCC3)(O)C2=CC=C(C=C2)F)=C/2\C(OC3=CC=CC=C3C\2=O)=O)C=C1 Chemical compound FC1=CC=C(C(=O)C=2/C(/C(N3C=2NCCC3)(O)C2=CC=C(C=C2)F)=C/2\C(OC3=CC=CC=C3C\2=O)=O)C=C1 YOGHDWYPXHDDHW-WCWDXBQESA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- KNMCTCABMSGXGR-UHFFFAOYSA-N 6-bromo-4-hydroxychromen-2-one Chemical compound C1=CC(Br)=CC2=C1OC(=O)C=C2O KNMCTCABMSGXGR-UHFFFAOYSA-N 0.000 description 3
- PLWSNELEFAXQBG-WCWDXBQESA-N ClC1=CC=C(C(=O)C=2/C(/C(N3C=2NCCC3)(O)C2=CC(=C(C=C2)F)F)=C/2\C(OC3=CC=CC=C3C\2=O)=O)C=C1 Chemical compound ClC1=CC=C(C(=O)C=2/C(/C(N3C=2NCCC3)(O)C2=CC(=C(C=C2)F)F)=C/2\C(OC3=CC=CC=C3C\2=O)=O)C=C1 PLWSNELEFAXQBG-WCWDXBQESA-N 0.000 description 3
- PNRYFQKVKURZNE-OCOZRVBESA-N OC1(\C(\C(=C2N1CCCN2)C(C1=CC=C(C=C1)C)=O)=C/1\C(OC2=CC=CC=C2C\1=O)=O)C1=CC=CC=C1 Chemical compound OC1(\C(\C(=C2N1CCCN2)C(C1=CC=C(C=C1)C)=O)=C/1\C(OC2=CC=CC=C2C\1=O)=O)C1=CC=CC=C1 PNRYFQKVKURZNE-OCOZRVBESA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- FSXWMFXMSFPEII-UHFFFAOYSA-N 1-(4-bromophenyl)-2-imidazolidin-2-ylideneethanone Chemical compound C1=CC(Br)=CC=C1C(=O)C=C1NCCN1 FSXWMFXMSFPEII-UHFFFAOYSA-N 0.000 description 2
- LCXYYYKMWYKEAG-UHFFFAOYSA-N 2-imidazolidin-2-ylidene-1-(4-methylphenyl)ethanone Chemical compound C1=CC(C)=CC=C1C(=O)C=C1NCCN1 LCXYYYKMWYKEAG-UHFFFAOYSA-N 0.000 description 2
- STMPGMKENCNIFM-UHFFFAOYSA-N 2-imidazolidin-2-ylidene-1-phenylethanone Chemical compound C=1C=CC=CC=1C(=O)C=C1NCCN1 STMPGMKENCNIFM-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000007092 Barton-Zard reaction Methods 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 238000006086 Paal-Knorr synthesis reaction Methods 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention discloses a chromone-substituted 2-hydroxypyrrole derivative and a synthesis method and application thereof, belonging to the technical field of medicinal chemistry. The structural formula of the chromone-substituted 2-hydroxypyrrole derivative is shown in the specificationWherein n is 0 or 1; r is hydrogen, fluorine, chlorine or methyl; r1Is hydrogen or fluorine; r2Is hydrogen, fluorine, chlorine or bromine; EWG is benzoyl, p-methylbenzoyl, p-fluorobenzoyl, p-chlorobenzoyl or p-bromobenzoyl. The invention adopts the benzoylformaldehyde derivative, the coumarin derivative and the heterocyclic ketene aminal as raw materials, and obtains the target compound chromone-substituted 2-hydroxypyrrole derivative with anti-inflammatory activity through a one-pot method series reaction.
Description
Technical Field
The invention relates to chromone-substituted 2-hydroxypyrrole derivatives, and a synthesis method and application thereof, and belongs to the technical field of pharmaceutical chemistry.
Background
Azoles are widely found in natural products and bioactive molecules. The pyrrole derivatives are widely used in the fields of anti-inflammation, antiemetic, blood pressure reduction, antidepressant, migraine treatment, anti-tumor and the like. For example, hydroxypyrroles have anti-inflammatory, antibacterial, antimicrobial, anti-tumor, antidepressant, and blood pressure lowering and heart rate slowing effects. To date, chemists and pharmacologists have established various synthetic methods and synthesized a large number of pyrrole compounds. From the aspect of constructing pyrrole skeleton, the synthesis methods mainly comprise Hantzsch, Knorr, Paal-Knorr, Barton-Zard, Huisgen method, cyclization, cycloaddition, transition metal-catalyzed C-H bond activation and the like. And examples of synthesizing an azole compound by three components without a metal catalyst are less common. The pyrrole compound synthesized by the existing method is generally a pyrrole compound with a simple structure, while the synthesis of the 2-hydroxypyrrole derivative is more difficult or the synthesis method of the derivative generally requires harsh conditions. Especially for synthesizing high-functional 2-hydroxypyrrole derivatives, such as chromone-substituted 2-hydroxypyrrole compounds, have not been reported at present.
Disclosure of Invention
The invention provides a chromone-substituted 2-hydroxypyrrole derivative, a synthetic method and application thereof, aiming at the problem of synthesizing 2-hydroxypyrrole compounds in the prior art, the invention adopts benzoyl formaldehyde derivatives, coumarin derivatives and heterocyclic ketene aminal as raw materials, and obtains the chromone-substituted 2-hydroxypyrrole derivatives which are target compounds with anti-inflammatory activity through a one-pot method series reaction.
Chromone-substituted 2-hydroxypyrrole derivatives having the formula (I):
wherein n is 0 or 1;
r is hydrogen, fluorine, chlorine or methyl;
R1is hydrogen or fluorine;
R2is hydrogen, fluorine, chlorine or bromine;
EWG is benzoyl, p-methylbenzoyl, p-fluorobenzoyl, p-chlorobenzoyl or p-bromobenzoyl.
The synthesis method of the chromone-substituted 2-hydroxypyrrole derivative comprises the following specific steps:
adding a benzoylformaldehyde derivative, a coumarin derivative and heterocyclic ketene aminal into a solvent, carrying out stirring reaction for 8-24 h under the conditions of heating reflux or 70-120 ℃ to obtain a reaction liquid, cooling the reaction liquid to room temperature, and carrying out purification treatment to obtain a chromone-substituted 2-hydroxypyrrole derivative with the structure of the formula (I); wherein the structural formula of the benzoyl formaldehyde derivative is shown as a formula (II), the structural formula of the coumarin derivative is shown as a formula (III), the structural formula of the heterocyclic ketene aminal is shown as a formula (IV),
in formula (II), R is hydrogen, fluorine, chlorine or methyl;
R1is hydrogen or fluorine;
in the formula (III), R2Hydrogen, fluorine, chlorine or bromine;
in formula (IV), n is 0 or 1;
EWG is benzoyl, p-methylbenzoyl, p-fluorobenzoyl, p-chlorobenzoyl or p-bromobenzoyl.
The synthetic reaction formula of the chromone-substituted 2-hydroxypyrrole derivative is
TLC detection and tracking are adopted in the reaction process, and the reaction yield is 60-90%;
the benzoyl formaldehyde derivative and the coumarin derivative are commercially available; heterocyclic ketene aminals according to the literature "z. -t.huang; m. -X.Wang, Synthesis,1992,12, 1273-; -j.li; C.D.Smith, Syn.Commun.2001,31, 527-;
preferably, the solvent is 1, 4-dioxane, ethanol, hydrogen peroxide or water.
Preferably, the mol ratio of the molar weight of the benzoyl formaldehyde derivative to the volume of the solvent is 1 (6-15);
preferably, the molar ratio of the benzoyl formaldehyde derivative, the coumarin derivative and the heterocyclic ketene aminal is 1:1: 1.
Preferably, the purification treatment is column chromatography or recrystallization.
More preferably, the eluent for column chromatography is a dichloromethane/petroleum ether mixed solvent, an ethyl acetate/petroleum ether mixed solvent or an ethyl acetate/acetone mixed solvent.
More preferably, the solvent for recrystallization is a dichloromethane/petroleum ether mixed solvent or an ethyl acetate/petroleum ether mixed solvent.
The chromone-substituted 2-hydroxypyrrole derivative is applied to the preparation of anti-inflammatory drugs.
The daily administration dosage of the chromone-substituted 2-hydroxypyrrole derivative in the anti-inflammatory drug is 0.01 mg-10 mg/kg.
Preferably, the chromone-substituted 2-hydroxypyrrole derivative is administered in an amount of 0.2mg to 10mg per kg per day in the anti-inflammatory agent.
The anti-inflammatory effect of the invention adopts NO detection method: mouse macrophage strain Raw 264.7 cells were purchased from american cell bank (ATCC) and cultured in DEME medium containing 10% FBS; raw 264.7 cells (2X 10)5One/well) is inoculated on a 24-well plate, compounds with different concentrations are added at the same time, the culture is carried out for 24 hours under the stimulation of LPS with the concentration of 1 mug/mL, and a solvent control and a non-irritant background control are additionally arranged; centrifuging to collect culture supernatant (5000rpm, 4 deg.C, 5min), and detecting NO in the supernatant by Griess method2 -The specific method comprises the following steps: with NaNO2And (3) diluting the standard substance in a gradient manner, adding 100 mu L of the standard substance into each well, adding 100 mu L of the collection culture medium into each sample well, adding 100 mu L of Griess reagent into each well, oscillating, detecting absorbance at 540nm of an enzyme-labeling instrument, calculating the content of NO in different sample wells according to the obtained standard curve, and calculating the inhibition rate of the compound, wherein the inhibition rate of NO is (concentration of NO in the combined action group-concentration of NO in LPS group)/concentration of NO in LPS group multiplied by 100%.
The invention has the beneficial effects that:
(1) the invention adopts the benzoyl formaldehyde derivative, the coumarin derivative and the heterocyclic ketene aminal as raw materials, and obtains the target compound chromone-substituted 2-hydroxypyrrole derivative with anti-inflammatory activity through the 'one-pot' series reaction, the method has the advantages of easily obtained synthetic raw materials, simple synthetic process, no need of a metal catalyst for reaction, low synthetic cost, and realization of synthesizing complex and various chromone-substituted 2-hydroxypyrrole derivatives without the catalyst, conciseness, high efficiency and the 'one-pot' method;
(2) the chromone-substituted 2-hydroxypyrrole derivative constructs a compound library of 2-hydroxypyrrole derivative compounds, and molecular diversity is realized;
(3) the chromone-substituted 2-hydroxypyrrole derivative has good anti-inflammatory activity and can be used for preparing anti-inflammatory drugs.
Drawings
FIG. 1 is a NMR spectrum of Compound 2 of example 2;
FIG. 2 is a NMR carbon spectrum of Compound 2 of example 2;
FIG. 3 is a NMR hydrogen spectrum of Compound 12 of example 12;
FIG. 4 is a NMR carbon spectrum of Compound 12 of example 12;
FIG. 5 is a single crystal structural diagram of Compound 21 of example 21.
Detailed Description
The present invention will be described in further detail with reference to specific embodiments, but the scope of the present invention is not limited to the description. The examples do not specify particular techniques or conditions, and are performed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available by purchase.
Example 1: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
The compound is named as (E) -3- (7-benzoyl-5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione and is marked as a compound 1;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (7-benzoyl-5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione) comprises the following specific steps:
adding 6mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding p-tolualdehyde hydrate, 4-hydroxycoumarin and 2- (imidazolidine-2-ylidene) -1-phenyleth-1-one, wherein the molar ratio of the p-tolualdehyde hydrate, the 4-hydroxycoumarin and the 2- (imidazolidine-2-ylidene) -1-phenyleth-1-one is 1:1:1, and the mol ratio of the molar amount of a phenylglyoxal derivative (tolualdehyde hydrate) to the volume of the solvent is 1: 6; heating and refluxing, stirring for reaction, detecting by TLC (thin layer chromatography) for 12H, completely reacting the raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (7-benzoyl-5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the (E) -3- (7-benzoyl-5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione is shown as follows;
(E) -3- (7-benzoyl-5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1, 2-a)]Structural characterization data for imidazol-6- (5H) -ylidene) chroman-2, 4-dione: (NMR, hydrogen Spectroscopy, deuterated dimethylsulfoxide, Bruker AM600 Instrument): delta-2.13 (s,3H, CH)3),3.21~3.24(m,1H,NCH2),3.70~3.75(m,1H,NCH2),4.10~4.14(m,2H,NHCH2),6.88~6.94(m,1H,ArH),7.03~7.06(m,3H,ArH),7.15~7.17(m,2H,ArH),7.26~7.28(m,2H,ArH),7.33~7.36(m,2H,ArH),7.63~7.66(m,3H,ArH),10.11(br,1H,NH),10.94(s,1H,OH);
(E) -3- (7-benzoyl-5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione (nmr carbon spectrum, deuterated dimethylsulfoxide, Bruker AM600 instrument): δ ═ 21.14,41.4,50.6,93.1,98.1,113.9,116.3,120.6,123.7,125.7,126.0,128.2,128.6,129.4,133.1,133.5,136.0,137.6,138.5,153.3,162.5,169.3,172.8,175.6,188.2;
this example (E) -3- (7-benzoyl-5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione in 76% yield and a melting point of 234.0 ℃;
high resolution mass spectrum C29H23N2O5[M+H]+Theoretical value 479.1601; found 479.1603.
Example 2: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
The compound was named (E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione as compound 2;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -subunit) chroman-2, 4-dione) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding benzoylformaldehyde, 4-hydroxycoumarin and 1- (4-chlorophenyl) -2- (imidazolidin-2-ylidene) ethan-1-one, wherein the molar ratio of the benzoylformaldehyde, the 4-hydroxycoumarin and the 1- (4-chlorophenyl) -2- (imidazolidin-2-ylidene) ethan-1-one is 1:1:1, and the mol ratio L of the molar amount of the benzoylformaldehyde derivative (benzoylformaldehyde) to the volume of the solvent is 1: 10; heating to 120 ℃, stirring for reaction, detecting by TLC (thin layer chromatography) for reaction for 8H, completely reacting the raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 3: 1;
(E) the synthetic reaction formula of the (E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione is shown as follows;
(E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1, 2-a)]The NMR spectrum of imidazole-6- (5H) -ylidene) chroman-2, 4-dione is shown in FIG. 1, (deuterated dimethyl sulfoxide, Bruker AM 500 instrument): delta-2.21 (s,3H, CH)3),3.29~3.30(d,1H,NCH2,J=27Hz),3.76~3.82(m,1H,NCH2),4.17~4.22(m,2H,NHCH2),7.00~7.02(m,1H,ArH),7.12~7.14(m,3H,ArH),7.22~7.24(m,2H,ArH),7.44~7.46(m,3H,ArH),7.71~7.75(m,3H,ArH),10.18(br,1H,NH),10.88(s,1H,OH);;
(E) The NMR spectrum of 3- (7- (4-chlorobenzoyl) -5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione is shown in FIG. 2, (deuterated dimethyl sulfoxide, Bruker AM 500 instrument): delta-21.1, 41.4,50.1,93.0,98.1,113.3,116.4,120.5,123.9,125.7,126.1,128.8,129.4,130.0,133.6,135.9,136.4,137.8,138.5,153.3,162.6,169.1,172.7,175.7,187.0;
this example (E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5- (p-tolyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione in 82% yield and a melting point of 225.8 ℃;
high resolution mass spectrum C29H22ClN2O5[M+H]+Theoretical value 513.1212 found 513.1209.
Example 3: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
Named (E) -3- (7-benzoyl-5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) -6-chlorochroman-2, 4-dione, as compound 3;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivatives ((E) -3- (7-benzoyl-5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) -6-chlorochroman-2, 4-dione) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding benzoyl formaldehyde hydrate, 6-chloro-4-hydroxycoumarin and 2- (imidazolidin-2-ylidene) -1-phenylethane-1-one, wherein the molar ratio of the benzoyl formaldehyde hydrate, the 6-chloro-4-hydroxycoumarin and the 2- (imidazolidin-2-ylidene) -1-phenylethane-1-one is 1:1:1, and the mol ratio of the molar weight of a benzoyl formaldehyde derivative (benzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; heating and refluxing, stirring for reaction, detecting by TLC (thin layer chromatography) for 10H, completely reacting the raw materials to obtain a reaction solution, cooling the reaction solution to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (7-benzoyl-5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) -6-chlorochroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the (E) -3- (7-benzoyl-5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) -6-chlorochroman-2, 4-diketone is shown as follows;
(E) -3- (7-benzoyl-5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1, 2-a)]Imidazole-6- (5H) -Subunit) -6-chlorochroman-2, 4-dione: (hydrogen nuclear magnetic resonance spectroscopy, deuterated dimethylsulfoxide, Bruker AM 500 instrument) < delta > 3.33-3.34 (m,1H, NCH)2),3.38~3.84(m,1H,NCH2),4.22~4.23(m,2H,NHCH2),7.03~7.05(m,1H,ArH),7.29~7.30(m,1H,ArH),7.30~7.38(m,6H,ArH),7.44~7.48(m,2H,ArH),7.63~7.64(m,1H,ArH),7.73~7.74(m,2H,ArH),10.31(br,1H,NH),10.80(s,1H,OH);
(E) -3- (7-benzoyl-5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) -6-chlorochroman-2, 4-dione: (nmr carbon spectrum, deuterated dimethylsulfoxide, Bruker AM 500 instrument): δ 41.4,50.2,93.1,97.9,114.8,118.6,121.9,124.9,125.7,128.1,128.3,128.6,128.9,129.2,133.1,133.2,137.3,138.7,151.8,162.0,169.3,172.1,174.0,188.1;
this example provides 78% yield of (E) -3- (7-benzoyl-5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) -6-chlorochroman-2, 4-dione having a melting point of 202.4 ℃;
high resolution mass spectrum C28H20ClN2O5[M+H]+Theoretical value 499.1055; found 499.1055.
Example 4: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
The compound is named as (E) -3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione and is marked as a compound 4;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -subunit) chroman-2, 4-diketone) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding benzoyl formaldehyde hydrate, 4-hydroxycoumarin and 1- (4-fluorophenyl) -2- (imidazolidine-2-ylidene) ethane-1-ketone, wherein the molar ratio of the benzoyl formaldehyde hydrate, the 4-hydroxycoumarin and the 1- (4-fluorophenyl) -2- (imidazolidine-2-ylidene) ethane-1-ketone is 1:1:1, and the mol ratio L of the molar amount of the benzoyl formaldehyde derivative (benzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; heating and refluxing, stirring for reaction, detecting by TLC (thin layer chromatography) for 10H, completely reacting the raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the (E) -3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione is shown as follows;
(E) -3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1, 2-a)]Imidazol-6- (5H) -ylidene) chroman-2, 4-dione: (hydrogen nuclear magnetic resonance spectroscopy, deuterated dimethylsulfoxide, Bruker AM 500 instrument) < delta > 3.28-3.32 (t,1H, NCH)2),3.79~3.84(m,1H,NCH2),4.16~4.25(m,1H,NHCH2),6.99~7.00(m,1H,ArH),7.12~7.15(m,1H,ArH),7.19~7.23(m,2H,ArH),7.26~7.28(m,1H,ArH),7.32~7.37(m,4H,ArH),7.43~7.46(m,1H,ArH),7.71~7.73(m,1H,ArH),7.80~7.83(m,1H,ArH),10.22(br,1H,NH),10.97(s,1H,OH);
(E) -3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione: (nmr carbon spectrum, deutero dimethyl sulfoxide, Bruker AM 500 instruments): δ 41.4,50.1,93.0,98.0,113.8,115.7(d, J22.5 Hz),116.3,120.5,123.8,125.7,126.0,128.8,129.2,131.1,133.6,134.3,138.9,153.3,162.5,164.0,166.0,169.3,175.7,186.8;
this example (E) -3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione in 83% yield and a melting point of 216.3 ℃;
high resolution mass spectrum C28H19FN2NaO5[M+Na]+Theoretical value 505.1170 found 505.1166.
Example 5: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
Named (E) -6-chloro-3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione as compound 5;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -6-chloro-3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -subunit) chroman-2, 4-diketone) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding benzoyl formaldehyde hydrate, 6-chloro-4-hydroxycoumarin and 1- (4-fluorophenyl) -2- (imidazolidine-2-ylidene) ethane-1-ketone, wherein the molar ratio of the benzoyl formaldehyde hydrate, the 6-chloro-4-hydroxycoumarin and the 1- (4-fluorophenyl) -2- (imidazolidine-2-ylidene) ethane-1-ketone is 1:1:1, and the mol ratio L of the molar amount of a benzoyl formaldehyde derivative (benzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; heating and refluxing, stirring for reaction, detecting by TLC (thin layer chromatography) for 10H, completely reacting the raw materials to obtain a reaction solution, cooling the reaction solution to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -6-chloro-3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the (E) -6-chloro-3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione is shown as follows;
(E) -6-chloro-3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1, 2-a)]Structural characterization data for imidazol-6- (5H) -ylidene) chroman-2, 4-dione; (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM600 instrument): delta is 3.32 to 3.34(m,1H, NCH)2),3.81~3.83(m,1H,NCH2),4.20~4.24(m,2H,NHCH2),7.06~7.07(m,1H,ArH),7.20~7.23(m,2H,ArH),7.28~7.29(m,1H,ArH),7.33~7.36(m,4H,ArH),7.47~7.49(m,1H,ArH),7.64~7.64(m,1H,ArH),7.79~7.82(M,2H,ArH),10.29(br,1H,NH),10.74(s,1H,OH);
E) -6-chloro-3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione: (nmr carbon spectrum, deuterated dimethylsulfoxide, Bruker AM600 instrument): δ 41.4,50.2,93.1,97.8,114.6,115.7(d, J21 Hz),118.7,121.9,125.0,125.7,128.1,129.0,131.1(d, J9 Hz),133.2,134.1,138.6,151.9,162.1,164.2,165.9,169.2,172.0,174.1,186.7;
this example (E) -6-chloro-3- (7- (4-fluorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione in 80% yield and melting point 199.8 ℃;
high resolution mass spectrum C28H19ClFN2O5[M+H]+Theoretical value 517.0961; found 517.0961.
Example 6: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
The compound is named as (E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione and is recorded as a compound 6;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -subunit) chroman-2, 4-diketone) comprises the following specific steps:
adding 10mL of ethanol serving as a solvent into a 25mL round-bottom flask, and then sequentially adding benzoyl formaldehyde hydrate, 4-hydroxycoumarin and 1- (4-chlorophenyl) -2- (imidazolidin-2-ylidene) ethan-1-one, wherein the molar ratio of the benzoyl formaldehyde hydrate, the 4-hydroxycoumarin and the 1- (4-chlorophenyl) -2- (imidazolidin-2-ylidene) ethan-1-one is 1:1:1, and the mol ratio of the molar amount of the benzoyl formaldehyde derivative (benzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; heating to 70 ℃, stirring for reaction, detecting by TLC (thin layer chromatography) for reaction for 24H, completely reacting raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the (E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione is shown as follows;
(E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1, 2-a)]Imidazol-6- (5H) -ylidene) chroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM600 instrument): δ 3.293-3.31 (m,1H, NCH)2),3.79~3.81(m,1H,NCH2),4.19~4.20(m,2H,NHCH2),7.00~7.01(m,1H,ArH),7.14~7.15(m,1H,ArH),7.27~7.28(m,1H,ArH),7.32~7.36(m,4H,ArH),7.44~7.47(m,3H,ArH),7.70~7.75(m,3H,ArH),10.21(br,1H,NH),10.86(s,1H,OH);
(E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione: (nmr carbon spectrum, deuterated dimethylsulfoxide, Bruker AM600 instrument): δ 41.4,50.1,93.0,98.1,113.4,116.4,120.5,123.9,125.7,126.0,126.3,128.8,128.8,129.2,130.0,133.7,136.4,137.8,138.8,153.3,169.2,176.9,186.9;
this example (E) -3- (7- (4-chlorobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione in 60% yield and a melting point of 222.4 ℃;
high resolution mass spectrum C28H20ClN2O5[M+H]+Theoretical value 499.1055; found 499.1055.
Example 7: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
The compound is named as (E) -3- (7- (4-bromobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) -6-chlorochroman-2, 4-dione and is marked as compound 7;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivatives ((E) -3- (7- (4-bromobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -subunit) -6-chlorochroman-2, 4-diketone) comprises the following specific steps:
adding 10mL of ethanol serving as a solvent into a 25mL round-bottom flask, and then sequentially adding benzoyl formaldehyde hydrate, 6-chloro-4-hydroxycoumarin and 1- (4-bromophenyl) -2- (imidazolidin-2-ylidene) ethan-1-one, wherein the molar ratio of the benzoyl formaldehyde hydrate, the 6-chloro-4-hydroxycoumarin and the 1- (4-bromophenyl) -2- (imidazolidin-2-ylidene) ethan-1-one is 1:1:1, and the mol ratio L of the molar weight of a benzoyl formaldehyde derivative (benzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; heating to 75 ℃, stirring for reaction, detecting by TLC (thin layer chromatography) for reaction for 20H, completely reacting the raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (7- (4-bromobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) -6-chlorochroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 1: 1;
(E) the synthetic reaction formula of the (E) -3- (7- (4-bromobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) -6-chlorochroman-2, 4-dione is shown as follows;
(E) -3- (7- (4-bromobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1, 2-a)]Imidazol-6- (5H) -ylidene) -6-chlorochroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM600 instrument): delta is 3.30 to 3.32(m,1H, NCH)2),3.80~3.82(m,1H,NCH2),4.21~4.22(m,2H,NHCH2),7.07~7.09(m,1H,ArH),7.28~7.29(m,5H,ArH),7.48~7.50(m,1H,ArH),7.59~7.67(m,5H,ArH),10.28(br,1H,NH),10.66(s,1H,OH);
(E) -3- (7- (4-bromobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) -6-chlorochroman-2, 4-dione: (nmr carbon spectrum, deuterated dimethylsulfoxide, Bruker AM600 instrument) δ 41.4,50.2,93.1,97.9,114.2,118.7,121.9,125.0,125.7,127.1,128.2,128.9,129.2,130.2,131.8,133.3,136.6,138.6,151.8,162.2,169.1,172.0,174.2,187.1;
this example provides 70% yield of (E) -3- (7- (4-bromobenzoyl) -5-hydroxy-5-phenyl-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) -6-chlorochroman-2, 4-dione, m.p. 225.7 ℃;
high resolution mass spectrum C28H19BrClN2O5[M+H]+Theoretical value 577.0160; found 577.0160.
Example 8: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
Designated (E) -3- (5- (3, 4-difluorophenyl) -5-hydroxy-7- (4-methylbenzoyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ethylene) chroman-2, 4-dione as compound 8;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (5- (3, 4-difluorophenyl) -5-hydroxy-7- (4-methylbenzoyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ethylidene) chroman-2, 4-diketone) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding 3, 4-difluorobenzoyl formaldehyde hydrate, 4-hydroxycoumarin and 2- (imidazolidine-2-ylidene) -1- (p-tolyl) ethan-1-one, wherein the molar ratio of the 3, 4-difluorobenzoyl formaldehyde hydrate, the 4-hydroxycoumarin and the 2- (imidazolidine-2-ylidene) -1- (p-tolyl) ethan-1-one is 1:1:1, and the mol: L of the molar amount of the benzoyl formaldehyde derivative (3, 4-difluorobenzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; heating to 110 ℃, stirring for reaction, detecting by TLC (thin layer chromatography) for reaction for 16H, completely reacting the raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (5- (3, 4-difluorophenyl) -5-hydroxy-7- (4-methylbenzoyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ethylidene) chroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of-3- (5- (3, 4-difluorophenyl) -5-hydroxy-7- (4-methylbenzoyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ethylidene) chroman-2, 4-dione is shown as follows;
(E) -3- (5- (3, 4-difluorophenyl) -5-hydroxy-7- (4-methylbenzoyl) -2, 3-dihydro-1H-pyrrolo [1, 2-a)]Imidazole-6- (5H) -ethylene) chroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM600 instrument); delta 2.25(s,3H, CH)3),3.38~3.43(m,1H,NCH2),3.79~3.81(d,J=10.0Hz,1H,NCH2),4.18~4.24(m,2H,NHCH2),7.00~7.02(m,1H,ArH),7.14~7.19(m,4H,ArH),7.39~7.48(m,3H,ArH),7.65~7.66(m,2H,ArH),7.74~7.75(m,1H,ArH),10.31(br,1H,NH),11.21(s,1H,OH);
(E) -3- (5- (3, 4-difluorophenyl) -5-hydroxy-7- (4-methylbenzoyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ethylene) chroman-2, 4-dione: (nuclear magnetic resonance carbon spectroscopy, deuterated dimethylsulfoxide, Bruker AM600 instrument); δ — 21.5,41.4,50.3,92.3,97.7,114.5,115.4,115.4,116.4,118.2,118.2,120.5,122.9,123.9,126.0,128.4,129.3,133.6,134.9,137.0,143.6,143.6,153.4,169.6,171.1,175.7,187.5;
this example shows 73% yield of (E) -3- (5- (3, 4-difluorophenyl) -5-hydroxy-7- (4-methylbenzoyl) -2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ethylene) chroman-2, 4-dione, melting point 197.8 ℃;
high resolution mass spectrum C29H20F2N2NaO5[M+Na]+Theoretical value 537.1232; found 537.1227.
Example 9: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
Designated (E) -3- (7- (4-chlorobenzoyl) -5- (3, 4-difluorophenyl) -5-hydroxy-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione as compound 9;
the synthesis method of the chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (7- (4-chlorobenzoyl) -5- (3, 4-difluorophenyl) -5-hydroxy-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -subunit) chroman-2, 4-diketone) comprises the following specific steps:
adding 10mL of hydrogen peroxide serving as a solvent into a 25mL round-bottom flask, and then sequentially adding 3, 4-difluorobenzoyl formaldehyde hydrate, 4-hydroxycoumarin and 1- (4-chlorophenyl) -2- (imidazolidine-2-subunit) ethane-1-ketone, wherein the molar ratio of the 3, 4-difluorobenzoyl formaldehyde hydrate to the 4-hydroxycoumarin to the 1- (4-chlorophenyl) -2- (imidazolidine-2-subunit) ethane-1-ketone is 1:1:1, and the mol ratio L of the molar amount of the benzoyl formaldehyde derivative (3, 4-difluorobenzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; heating to 90 ℃, stirring for reaction, detecting by TLC (thin layer chromatography) for reaction for 10H, completely reacting raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (7- (4-chlorobenzoyl) -5- (3, 4-difluorophenyl) -5-hydroxy-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -ylidene) chroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the-3- (7- (4-chlorobenzoyl) -5- (3, 4-difluorophenyl) -5-hydroxy-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazole-6- (5H) -subunit) chroman-2, 4-diketone is shown as follows;
(E) -3- (7- (4-chlorobenzoyl) -5- (3, 4-difluorophenyl) -5-hydroxy-2, 3-dihydro-1H-pyrrolo [1, 2-a)]Imidazol-6- (5H) -ylidene) chroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM600 instrument); delta is 3.34 to 3.42(m,1H, NCH)2),3.78~3.83(m,1H,NHCH2),4.17~4.26(m,1H,NHCH2),7.02~7.04(m,1H,ArH),7.14~7.17(m,2H,ArH),7.39~7.49(m,5H,ArH),7.34~7.78(m,3H,ArH),10.32(br,1H,NH),10.99(s,1H,OH);
(E) -3- (7- (4-chlorobenzoyl) -5- (3, 4-difluorophenyl) -5-hydroxy-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione: (nmr carbon spectrum, deuterated dimethylsulfoxide, Bruker AM600 instrument): δ 41.3,50.3,92.2,97.9,113.6,115.4,116.4,118.1,120.4,122.9,124.0,126.0,128.8,130.0,133.8,136.6,136.9,137.9,149.7(d, J244.5 Hz),149.9(d, J244.5 Hz),153.4,162.5,169.3,171.6,175.8,186.8;
this example provides 77% yield of (E) -3- (7- (4-chlorobenzoyl) -5- (3, 4-difluorophenyl) -5-hydroxy-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione, m.p. 217.7 ℃;
high resolution mass spectrum C28H17ClF2N2NaO5[M+H]+Theory 557.0686; found 557.0684.
Example 10: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
Designated (E) -3- (7- (4-chlorobenzoyl) -5- (3, 4-difluorophenyl) -5-hydroxy-2, 3-dihydro-1H-pyrrolo [1,2-a ] imidazol-6- (5H) -ylidene) chroman-2, 4-dione as compound 10;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-methylchroman-2, 4-dione) comprises the following specific steps:
adding 10mL of water serving as a solvent into a 25mL round-bottom flask, and then sequentially adding p-tolualdehyde hydrate, 6-methyl-4-hydroxycoumarin and 1-phenyl-2- (tetrahydropyrimidine-2 (1H) -ylidene) ethan-1-one, wherein the molar ratio of the p-tolualdehyde hydrate, the 6-methyl-4-hydroxycoumarin and the 1-phenyl-2- (tetrahydropyrimidine-2 (1H) -ylidene) ethan-1-one is 1:1:1, and the mol: L of the molar amount of a phenylglyoxal derivative (p-tolualdehyde hydrate) to the volume of the solvent is 1: 10; heating and refluxing, stirring for reaction, detecting by TLC (thin layer chromatography) for 20H, completely reacting the raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-methylchroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the (E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-methylchroman-2, 4-dione is shown as follows;
(E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1, 2-a)]Pyrimidin-7 (6H) -ylidene) -6-methylchroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM 500 instrument); δ is 1.86 to 1.88(m,1H, CH)2),1.96~1.98(m,1H,CH2),2.21(s,3H,CH3),2.25(s,3H,CH3),2.90~2.94(m,1H,NCH2),3.43~3.52(m,3H,NHCH2,NCH2),6.81~6.83(m,1H,ArH),7.11~7.12(m,2H,ArH),7.20~7.22(m,3H,ArH),7.31~7.34(m,2H,ArH),7.40~7.43(m,1H,ArH),7.52~7.53(m,1H,ArH),7.72~7.74(m,2H,ArH),9.27(br,1H,NH),11.56(s,1H,OH);
(E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) -6-methylchroman-2, 4-dione: (nuclear magnetic resonance carbon spectroscopy, deuterated dimethylsulfoxide, Bruker AM 500 instrument); δ -19.1, 20.7,21.1,37.1,39.1,96.5,96.8,116.0,116.6,120.3,125.5,125.8,128.4,128.5,129.4,132.7,133.1,133.9,135.9,137.6,138.5,151.4,158.5,160.0,162.7,175.2,189.2;
this example (E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) -6-methylchroman-2, 4-dione in 88% yield and a melting point of 225.8 ℃;
high resolution mass spectrum C31H26N2NaO5[M+Na]+Theory 529.1734; found 529.1736.
Example 11: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
The compound is named as (E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione and is marked as a compound 11;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding p-tolualdehyde hydrate, 6-methyl-4-hydroxycoumarin and 1-phenyl-2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone, wherein the molar ratio of the p-tolualdehyde hydrate, the 6-methyl-4-hydroxycoumarin and the 1-phenyl-2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone is 1:1:1, and the mol ratio L of the molar amount of a phenylglyoxal derivative (p-tolualdehyde hydrate) to the volume of the solvent is 1: 10; heating and refluxing, stirring for reaction, detecting by TLC (thin layer chromatography) for 10H, completely reacting the raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the (E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione is shown as follows;
(E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1, 2-a)]Pyrimidin-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM 500 instrument); δ is 1.78 to 1.79(m,2H, CH)2),2.13(s,3H,CH3),2.83~2.86(t,1H,NHCH2),3.35~3.44(m,3H,NHCH2,NCH2),6.88~6.90(m,1H,ArH),7.03~7.15(m,7H,ArH),7.32~7.35(m,1H,ArH),7.65~7.73(m,3H,ArH),9.20(br,1H,NH),11.32(s,1H,OH);
(E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione: (nmr carbon spectrum, deutero dimethyl sulfoxide, Bruker AM 500 instruments): δ 19.0,21.1,37.2,39.1,96.3,96.8,115.5(d, J21.3 Hz),116.2,116.7,120.6,123.6,125.8,125.9,131.3,133.2,134.3,135.8,138.6,153.3,158.3,164.0,163.6(d, J242.5 Hz),166.0,175.2,187.8;
this example (E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione in 89% yield and melting point 210.6 ℃;
high resolution mass spectrum C30H24ClN2O5[M+H]+527.1368, theory 527.1368; found 527.1368.
Example 12: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
The compound is named as (E) -3- (8- (4-fluorobenzoyl) -6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione and is marked as compound 12;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8- (4-fluorobenzoyl) -6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) chroman-2, 4-dione) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding p-tolualdehyde hydrate, 4-hydroxycoumarin and 1- (4-fluorophenyl) -2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone, wherein the molar ratio of the p-tolualdehyde hydrate, the 4-hydroxycoumarin and the 1- (4-fluorophenyl) -2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone is 1:1:1, and the mol ratio L of the molar amount of a phenylglyoxal derivative (p-tolualdehyde hydrate) to the volume of the solvent is 1: 10; heating and refluxing, stirring for reaction, detecting by TLC (thin layer chromatography) for 10H, completely reacting the raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8- (4-fluorobenzoyl) -6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) chroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the (E) -3- (8- (4-fluorobenzoyl) -6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione is shown as follows;
(E) a hydrogen nuclear magnetic resonance spectrum of 3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione (deuterated dimethyl sulfoxide, Bruker AM 500 instrument): δ ═ 1.78-1.79 (m,2H, CH2),2.13(s,3H, CH3), 2.83-2.86 (t,1H, NHCH2), 3.35-3.44 (m,3H, NHCH2, NCH2), 6.88-6.90 (m,1H, ArH), 7.03-7.15 (m,7H, ArH), 7.32-7.35 (m,1H, ArH), 7.65-7.73 (m,3H, ArH),9.20(br H, 1H, NH 11H, 11H);
(E) a nmr carbon spectrum of 3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione is shown in fig. 4, (deuterated dimethyl sulfoxide, Bruker AM 500 instrument): δ ═ 19.0,21.1,37.2,39.1,96.3,96.8,115.5(d, J ═ 21.3Hz),116.2,116.7,120.6,123.6,125.8,125.9,131.3,133.2,134.3,135.8,138.6,153.3,158.3,164.0,163.6(d, J ═ 242.5Hz),166.0,175.2,187.8;
this example (E) -3- (8-benzoyl-6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione in 90% yield and a melting point of 242.8 ℃;
high resolution mass spectrum C30H24FN2O5[M+H]+ theoretical 511.1664; found 511.1664.
Example 13: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
The compound is named as (E) -3- (8- (4-chlorobenzoyl) -6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) -6-methylchroman-2, 4-dione, and is marked as compound 13;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8- (4-chlorobenzoyl) -6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-methylchroman-2, 4-dione) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding p-tolualdehyde hydrate, 6-methyl-4-hydroxycoumarin and 1- (4-chlorophenyl) -2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone, wherein the molar ratio of the p-tolualdehyde hydrate, the 6-methyl-4-hydroxycoumarin and the 1- (4-chlorophenyl) -2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone is 1:1:1, and the mol ratio of the molar amount of a phenylglyoxal derivative (p-tolualdehyde hydrate) to the volume of the solvent is 1: 10; heating and refluxing, stirring for reaction, detecting by TLC (thin layer chromatography) for 10H, completely reacting the raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8- (4-chlorobenzoyl) -6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-methylchroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the (E) -3- (8- (4-chlorobenzoyl) -6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-methylchroman-2, 4-dione is shown as follows;
(E) -3- (8- (4-chlorobenzoyl) -6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a]Pyrimidin-7 (6H) -ylidene) -6-methylchroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM600 instrument); delta is 1.80-1.97 (m,2H, CH)2,),2.21(s,3H,CH3),2.26(s,2H,CH3),2.92~2.93(m,1H,NCH2),3.47~3.51(m,3H,NCH2,NHCH2,NHCH2),6.86~6.87(m,1H,ArH),7.11~7.12(m,2H,ArH),7.20~7.24(m,3H,ArH),7.42~7.44(m,2H,ArH),7.52(m,1H,ArH),7.71~7,73(m,2H,ArH),9.26(br,1H,NH),11.41(s,1H,OH);
(E) -3- (8- (4-chlorobenzoyl) -6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) -6-methylchroman-2, 4-dione, (nmr carbon spectroscopy, deuterated dimethyl sulfoxide, Bruker AM600 instrument); δ -19.1, 20.7,21.1,37.1,39.6,96.5,96.8,116.0,116.2,120.2,125.6,125.7,128.6,129.4,130.2,132.8,134.1,135.8,136.5,137.7,138.5,151.4,158.3,162.8,165.0,175.4,188.0;
this example (E) -3- (8- (4-chlorobenzoyl) -6-hydroxy-6- (p-tolyl) -1,2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) -6-methylchroman-2, 4-dione in 87% yield and a melting point of 220.0 ℃;
high resolution mass spectrum C31H25ClN2NaO5[M+Na]+Theory 563.1344; found 563.1343.
Example 14: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
Named (E) -3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione as compound 14;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -subunit) chroman-2, 4-diketone) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding benzoyl formaldehyde hydrate, 4-hydroxycoumarin and 2- (tetrahydropyrimidine-2 (1H) -ylidene) -1- (p-tolyl) ethan-1-one, wherein the molar ratio of the benzoyl formaldehyde hydrate, the 4-hydroxycoumarin and the 2- (tetrahydropyrimidine-2 (1H) -ylidene) -1- (p-tolyl) ethan-1-one is 1:1:1, and the molar ratio of the molar weight of a benzoyl formaldehyde derivative (benzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; stirring and reacting at the temperature of 80 ℃, detecting by TLC (thin layer chromatography) for 10H, completely reacting raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography separation to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -subunit) chroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the-3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) chroman-2, 4-dione is shown as follows;
(E) -3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1, 2-a)]Pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM 500 instrument); delta is 1.87 to 1.96(m,2H, CH)2,),2.22(s,3H,CH3),2.90~2.93(m,1H,NCH2),3.40~3.41(m,1H,NCH2),3.50~3.53(m,2H,NHCH2),6.94~6.95(m,1H,ArH),7.10~7.15(m,3H,ArH),7.26~7.35(m,5H,ArH),7.40~7.42(m,1H,ArH),7.65~7.67(m,2H,ArH),7.73~7.74(m,1H,ArH),9.28(br,1H,NH),11.59(s,1H,OH);
(E) -3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione: (nuclear magnetic resonance carbon spectroscopy, deuterated dimethylsulfoxide, Bruker AM 500 instrument); δ -19.1, 21.5,37.2,39.1,96.3,96.8,116.2,117.3,120.6,123.6,125.8,125.9,128.6,128.8,129.1,129.2,133.1,135.1,138.8,143.5,153.3,158.6,162.5,164.0,175.2,188.7;
this example (E) -3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione in 85% yield and a melting point of 214.7 ℃;
high resolution mass spectrum C30H25N2O5[M+H]+Theory 493.1758; found 493.1762.
Example 15: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
Named (E) -6-bromo-3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione as compound 15;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -6-bromo-3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -subunit) chroman-2, 4-diketone) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding benzoyl formaldehyde hydrate, 4-hydroxycoumarin and 2- (tetrahydropyrimidine-2 (1H) -ylidene) -1- (p-tolyl) ethan-1-one, wherein the molar ratio of the benzoyl formaldehyde hydrate, the 6-bromo-4-hydroxycoumarin and the 2- (tetrahydropyrimidine-2 (1H) -ylidene) -1- (p-tolyl) ethan-1-one is 1:1:1, and the mol ratio L of the molar amount of a benzoyl formaldehyde derivative (benzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; stirring and reacting at the temperature of 100 ℃, detecting by TLC (thin layer chromatography) for 10H, completely reacting raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography separation to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -6-bromo-3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) chroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the-6-bromo-3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) chroman-2, 4-dione is shown as follows;
(E) -6-bromo-3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1, 2-a)]Pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM600 instrument); delta is 1.90-1.97 (m,2H, CH)2),2.22(s,3H,CH3),2.92~2.94(t,1H,NCH2),3.44~3.54(m,3H,NCH2,NHCH2),6.94~6.96(m,1H,ArH),7.14~7.16(m,2H,ArH),7.27~7.27(m,5H,ArH),7.54~7.55(m,1H,ArH),7.65~7.67(m,2H,ArH),7.80~7.80(m,1H,ArH),9.36(br,1H,NH),11.32(s,1H,OH);
(E) -6-bromo-3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione: (nuclear magnetic resonance carbon spectroscopy, deuterated dimethylsulfoxide, Bruker AM600 instrument); δ 19.0,21.5,37.2,39.1,96.1,96.8,115.6,118.0,118.8,122.5,125.8,127.9,128.7,128.9,129.1,129.2,134.9,135.5,138.6,143.7,151.8,158.5,162.1,163.5,173.7,188.6;
this example (E) -6-bromo-3- (6-hydroxy-8- (4-methylbenzoyl) -6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione in 87% yield and melting point 234.2 ℃;
high resolution mass spectrum C30H24BrN2O5[M+H]+Theory 571.0863; found 571.0864.
Example 16: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
The compound is named as (E) -3- (8-benzoyl-6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione and is marked as a compound 16;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8-benzoyl-6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) chroman-2, 4-dione) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding benzoyl formaldehyde hydrate, 4-hydroxycoumarin and 1-phenyl-2- (tetrahydropyrimidine-2 (1H) -ylidene) ethan-1-one, wherein the molar ratio of the benzoyl formaldehyde hydrate, the 6-bromo-4-hydroxycoumarin and the 1-phenyl-2- (tetrahydropyrimidine-2 (1H) -ylidene) ethan-1-one is 1:1:1, and the mol: L ratio of the molar amount of the benzoyl formaldehyde derivative (benzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; stirring and reacting at the temperature of 110 ℃, detecting by adopting TLC (thin layer chromatography) for 10H, completely reacting raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography separation to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8-benzoyl-6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -subunit) chroman-2, 4-diketone); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the-3- (8-benzoyl-6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) chroman-2, 4-dione is shown as follows;
(E) -3- (8-benzoyl-6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1, 2-a)]Pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM 500 instrument); δ is 1.88 to 1.99(m,2H, CH)2),2.91~2.94(m,1H,NCH2),3.44~3.55(m,3H,NCH2,NHCH2),6.92~6.93(m,1H,ArH),7.10~7.12(m,1H,ArH),7.25~7.43(m,9H,ArH),7.72~7.75(m,3H,ArH),9.31(br,1H,NH),11.54(s,1H,OH);
(E) -3- (8-benzoyl-6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione: (nuclear magnetic resonance carbon spectroscopy, deuterated dimethylsulfoxide, Bruker AM 500 instrument); δ 19.1,37.2,39.1,96.4,96.8,116.1,117.0,120.6,123.6,125.8,125.8,128.4,128.5,128.8,129.2,133.1,133.1,137.6,138.8,153.3,158.5,162.6,164.5,175.2,189.2;
this example (E) -3- (8-benzoyl-6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione in 87% yield and melting point at 253.1 ℃;
high resolution mass spectrum C29H23N2O5[M+H]+Theory 479.1601; found 479.1600.
Example 17: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
Named (E) -6-chloro-3- (8- (4-chlorobenzoyl) -6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione as compound 17;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -6-chloro-3- (8- (4-chlorobenzoyl) -6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -subunit) chroman-2, 4-diketone) comprises the following steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding benzoyl formaldehyde hydrate, 4-hydroxycoumarin and 1- (4-fluorophenyl) -2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone, wherein the molar ratio of the benzoyl formaldehyde hydrate, the 6-bromo-4-hydroxycoumarin and the 1- (4-fluorophenyl) -2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone is 1:1:1, and the mol ratio of the molar amount of a benzoyl formaldehyde derivative (benzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; stirring and reacting at the temperature of 120 ℃, detecting by TLC (thin layer chromatography) for 12H, completely reacting raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography separation to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -6-chloro-3- (8- (4-chlorobenzoyl) -6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) chroman-2, 4-dione); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the-6-chloro-3- (8- (4-chlorobenzoyl) -6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) chroman-2, 4-dione is shown as follows;
(E) -6-chloro-3- (8- (4-chlorobenzoyl) -6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1, 2-a)]Pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM600 instrument); delta is 1.89 to 1.98(m,2H, CH)2),2.91~2.94(m,1H,NCH2),3.43~3.53(m,3H,NCH2,NHCH2),7.03~7.04(m,1H,ArH),7.27~7.9(m,1H,ArH),7.31~7.33(m,4H,ArH),7.43~7.46(m,3H,ArH),7.65~7.65(m,2H,ArH),7.74(m,1H,ArH),9.37(br,1H,NH),11.16(s,1H,OH);
(E) -6-chloro-3- (8- (4-chlorobenzoyl) -6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione: (nuclear magnetic resonance carbon spectroscopy, deuterated dimethylsulfoxide, Bruker AM600 instrument); δ 19.0,37.2,39.2,96.2,96.8,117.3,118.6,121.9,124.9,128.0,125.8,128.7,128.9,129.3,130.3,132.9,136.3,138.0,138.4,151.8,158.4,162.3,164.0,173.8,188.0;
this example (E) -6-chloro-3- (8- (4-chlorobenzoyl) -6-hydroxy-6-phenyl-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione in 87% yield and melting point 247.2 ℃;
high resolution mass spectrum C29H20Cl2N2NaO5[M+Na]+Theory 569.0461; found 569.0463.
Example 18: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
The compound is named as (E) -3- (8-benzoyl-6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione and is marked as a compound 18;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8-benzoyl-6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-chlorochroman-2, 4-diketone) comprises the following steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding benzoyl formaldehyde hydrate, 6-chloro-4-hydroxycoumarin and 1- (4-chlorophenyl) -2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone, wherein the molar ratio of the benzoyl formaldehyde hydrate, the 6-chloro-4-hydroxycoumarin and the 1- (4-chlorophenyl) -2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone is 1:1:1, and the mol ratio of the molar amount of a benzoyl formaldehyde derivative (benzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; stirring and reacting at the temperature of 110 ℃, detecting by TLC (thin layer chromatography) for 14H, completely reacting raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography separation to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8-benzoyl-6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -subunit) -6-chlorochroman-2, 4-diketone); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the (E) -3- (8-benzoyl-6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) -6-chlorochroman-2, 4-diketone is shown as follows;
(E) -3- (8-benzoyl-6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1, 2-a)]Pyrimidin-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione: (nmr hydrogen spectroscopy, deuterated dimethylsulfoxide, Bruker AM 5600 instrument); delta is 1.90-1.99 (m,2H, CH)2),2.94~2.98(m,1H,NCH2),3.44~3.55(m,3H,NCH2,NHCH2),7.00~7.01(m,1H,ArH),7.15~7.18(m,2H,ArH),7.32~7.39(m,4H,ArH),7.41~7.45(m,.2H,ArH),7.65~7.66(m,1H,ArH),7.73~7.74(m,2H,ArH),9.42(br,1H,NH),11.34(s,1H,OH);
(E) -3- (8-benzoyl-6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione: (nuclear magnetic resonance carbon spectroscopy, deuterated dimethylsulfoxide, Bruker AM600 instrument); 19.0,37.2,39.2,96.1,96.4,115.8(d, J ═ 21Hz),117.8,118.5,121.9,124.8,128.0,128.2,128.5,128.6,132.8,133.3,134.8,137.3,151.8,158.4,162.4(d, J ═ 243Hz),162.9(d, J ═ 220Hz),173.7,189.1;
this example gives 89% yield of (E) -3- (8-benzoyl-6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) -6-chlorochroman-2, 4-dione having a melting point of 270.6 ℃;
high resolution mass spectrum C29H21ClFN2O5[M+H]+Theory 531.1118; found 531.1116.
Example 19: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
Designated (E) -3- (8- (4-fluorobenzoyl) -6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione as compound 19;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8- (4-fluorobenzoyl) -6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -subunit) chroman-2, 4-diketone) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding p-fluorobenzoyl formaldehyde hydrate, 6-chloro-4-hydroxycoumarin and 1-phenyl-2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone, wherein the molar ratio of the p-fluorobenzoyl formaldehyde hydrate, the 6-chloro-4-hydroxycoumarin and the 1-phenyl-2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone is 1:1:1, and the mol ratio of the molar amount of a phenylglyoxal derivative (p-fluorobenzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; stirring and reacting under a reflux condition, detecting and reacting for 10H by adopting TLC (thin layer chromatography), completely reacting raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography separation to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8- (4-fluorobenzoyl) -6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -subunit) chroman-2, 4-diketone); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the (E) -3- (8- (4-fluorobenzoyl) -6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -ylidene) chroman-2, 4-dione is shown as follows;
(E) -3- (8- (4-fluorobenzoyl) -6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1, 2-a)]Pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM 500 instrument); delta is 1.89 to 1.98(m,2H, CH)2),2.92~2.97(m,,1H,NHCH2),3.50~3.55(m,1H,NHCH2),3.50~3.55(m,2H,NCH2),6.97~6.98(m,1H,ArH),7.12~7.20(m,5H,ArH),7.36~7.45(m,1H,ArH),7.73~7.82(m,3H,ArH),9.34(br,1H,NH),11.52(s,1H,OH);
(E) -3- (8- (4-fluorobenzoyl) -6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione: (nuclear magnetic resonance carbon spectroscopy, deuterated dimethylsulfoxide, Bruker AM 500 instrument); δ 20.1,38.2,40.2,97.2,94.4,116.7,117.3,117.9,121.5,124.7,126.9,129.2(d, J ═ 8.8Hz),129.2(d, J ═ 8.8Hz),132.3(d, J ═ 8.8Hz),134.3,135.3,136.0,154.3,159.4,163.3(d, J ═ 243.8Hz),163.6,165.1,167.0,176.4,188.8;
this example gives 86% yield of (E) -3- (8- (4-fluorobenzoyl) -6- (4-fluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione having a melting point of 247.4 ℃;
high resolution mass spectrum C29H21F2N2O5[M+H]+Theory 515.1413; found 515.1413.
Example 20: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
Designated (E) -3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione as compound 20;
the synthesis method of chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -subunit) chroman-2, 4-diketone) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding p-fluorobenzoyl formaldehyde hydrate, 4-hydroxycoumarin and 1- (4-fluorophenyl) -2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone, wherein the molar ratio of the p-fluorobenzoyl formaldehyde hydrate, the 4-hydroxycoumarin and the 1- (4-fluorophenyl) -2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone is 1:1:1, and the mol ratio of the molar amount of a benzoylaldehyde derivative (p-fluorobenzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; stirring and reacting under a reflux condition, detecting and reacting for 10 hours by adopting TLC (thin layer chromatography), completely reacting raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography separation to obtain a chromone-substituted 2-hydroxypyrrole derivative ((E) -3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -subunit) chroman-2, 4-diketone); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
(E) the synthetic reaction formula of the-3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7 (6H) -subunit) chroman-2, 4-diketone is shown as follows;
(E) -3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1, 2-a)]Pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione: (hydrogen nuclear magnetic resonance, deuterated dimethylsulfoxide, Bruker AM 500 instrument); δ is 1.95 to 1.96(m,2H, CH)2),2.96~3.00(m,1H,NCH2),3.41~3.55(m,3H,NCH2,NHCH2),6.98~7.00(m,1H,ArH),7.13~7.16(m,2H,ArH),7.37~7.46(m,5H,ArH),7.73~7.76(m,3H,ArH),9.39(br,1H,NH),11.57(s,1H,OH);13C NMR(125MHz,DMSO):δ=19.9,36.5,39.7,95.8,96.0,115.5(d,J=18.8Hz),116.3,116.8,118.2(d,J=7.5Hz),120.4,123.0,123.8,125.9,128.7,130.2,133.4,136.3,136.7,137.9,149.5(d,J=243.8Hz),149.7(d,J=250Hz),153.3,158.5,162.7,163.4,175.4,187.9;
(E) -3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione: (nuclear magnetic resonance carbon spectroscopy, deuterated dimethylsulfoxide, Bruker AM 500 instrument); δ 19.9,36.5,39.7,95.8,96.0,115.5(d, J ═ 18.8Hz),116.3,116.8,118.2(d, J ═ 7.5Hz),120.4,123.0,123.8,125.9,128.7,130.2,133.4,136.3,136.7,137.9,149.5(d, J ═ 243.8Hz),149.7(d, J ═ 250Hz),153.3,158.5,162.7,163.4,175.4,187.9;
this example (E) -3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7 (6H) -ylidene) chroman-2, 4-dione in 80% yield and melting point 219.1 ℃;
high resolution mass spectrum C29H20F2N2NaO5[M+Na]+Theoretical, 571.0843, found, 571.0843.
Example 21: the structure of the chromone-substituted 2-hydroxypyrrole derivative of this example is shown in the following formula
Designated 3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7- (6H) -ylidene) chroman-2, 4-dione as compound 21;
the synthesis method of the chromone-substituted 2-hydroxypyrrole derivative (3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7- (6H) -subunit) chroman-2, 4-diketone) comprises the following specific steps:
adding 10mL of 1, 4-dioxane serving as a solvent into a 25mL round-bottom flask, and sequentially adding 3, 4-difluorobenzoyl formaldehyde hydrate, 4-hydroxycoumarin and 1- (4-chlorophenyl) -2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone, wherein the molar ratio of the 3, 4-difluorobenzoyl formaldehyde hydrate, the 4-hydroxycoumarin and the 1- (4-chlorophenyl) -2- (tetrahydropyrimidine-2 (1H) -ylidene) ethane-1-ketone is 1:1:1, and the mol ratio of the molar amount of the benzoyl formaldehyde derivative (3, 4-difluorobenzoyl formaldehyde hydrate) to the volume of the solvent is 1: 10; stirring and reacting under a reflux condition, detecting and reacting for 10 hours by adopting TLC (thin layer chromatography), completely reacting raw materials to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying by column chromatography separation to obtain a chromone-substituted 2-hydroxypyrrole derivative (3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7- (6H) -subunit) chroman-2, 4-diketone); wherein the column chromatography eluent is a mixed solvent of ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is 2: 1;
the synthesis reaction formula of 3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidine-7- (6H) -subunit) chroman-2, 4-diketone is shown as follows;
3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1, 2-a)]Pyrimidin-7- (6H) -ylidene) chroman-2, 4-dione: (NMR, hydrogen spectrum, deuterated dimethyl sulfoxide, Bruker AM 500 instrument) < delta > 2.02(s,2H, CH2), 3.45-3.54 (m,2H, NCH2), 3.75-7.77 (m,2H, NHCH)2),6.88~6.89(m,2H,ArH),7.06~7.08(m,2H,ArH),7.13~7.15(m,2H,ArH),7.19~7.30(m,6H,ArH),7.47~7.55(s,1H,ArH),7.55~7.56(m,1H,ArH),7.99(br,1H,NH),10.76(s,1H,OH);
3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7- (6H) -ylidene) chroman-2, 4-dione: (NMR carbon Spectroscopy, deuterated dimethylsulfoxide, Bruker AM 500 instrument): δ ═ 21.3,38.3,42.0,100.7,102.2,107.5,115.9,116.0,123.5,124.0,127.01,127.7,127.9,128.0,129.5,131.2,132.2,133.4,141.2,148.7,152.6,161.5,162.1,187.4;
this example provides 87% yield of 3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7- (6H) -ylidene) chroman-2, 4-dione as shown at 224.3 ℃;
high resolution mass spectrum C29H22ClN2O4[M+H]+Theory 497.1263; found, 497.1268;
the single crystal structure of 3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7- (6H) -ylidene) chroman-2, 4-dione of this example is shown in fig. 5. as can be seen from fig. 5, the crystal data and the structure refinement data are shown in table 1, and the single crystal structure is 3- (8- (4-chlorobenzoyl) -6- (3, 4-difluorophenyl) -6-hydroxy-1, 2,3, 4-tetrahydropyrrolo [1,2-a ] pyrimidin-7- (6H) -ylidene) chroman-2, 4-dione;
table 1 crystal data and structure refinement
The chromone-substituted 2-hydroxypyrrole derivatives of examples 1-21 have the structural formulas shown in Table 2;
TABLE 2 chromone-substituted 2-hydroxypyrrole derivatives structural formulas and numbering
Anti-inflammatory effects were measured using NO assay: mouse macrophage strain Raw 264.7 cells were purchased from the U.S. cell bank (ATCC) and cultured in DEME medium containing 10% FBS. Raw 264.7 cells (2X 10)5One/well) were inoculated in 24-well plates, while adding different concentrations of the compound, incubated for 24h under 1 μ g/ml LPS stimulation, and a solvent control and a non-irritant background control were added. Centrifuging to collect culture supernatant (5000rpm, 4 deg.C, 5min), and detecting NO in the supernatant by Griess method2 -The specific method comprises the following steps: with NaNO2Diluting a standard substance in a gradient manner, adding 100 mu l of the standard substance into each hole, adding 100 mu l of a collecting culture medium into each sample hole, then adding 100 mu l of Griess reagent into each hole, oscillating, detecting absorbance at 540nm of an enzyme-labeling instrument, calculating the NO content of different sample holes according to the obtained standard curve, and calculating the inhibition rate of a compound, wherein the inhibition rate of NO is (the concentration of NO in a combined action group-the concentration of NO in an LPS group)/the concentration of NO in the LPS group multiplied by 100%;
the anti-inflammatory activity test of the chromone-substituted 2-hydroxypyrrole derivatives synthesized in examples 1-21 showed that the chromone-substituted 2-hydroxypyrrole derivatives synthesized in examples 1-21 have better anti-inflammatory activity against mouse macrophage strain Raw 264.7 (see Table 3),
TABLE 3 chromonyl-substituted 2-hydroxypyrrole derivatives have inhibitory activity on mouse macrophage strain Raw 264.7
As can be seen from Table 3, IC of Compound 950(μmol/L) 8.91; IC of Compound 1150(μmol/L) 8.40; IC of Compound 1350(μmol/L) 3.41; IC of Compound 1550(μmol/L) 7.07; IC of Compound 1850(. mu. mol/L) 7.63, IC of these five compounds50The concentration of the five compounds is less than 10 mu mol/L, and the five compounds show more excellent anti-inflammatory activity; and the IC50 of the compounds 10, 12, 14, 19 and 21 is less than 20 mu mol/L, which shows that the five compounds have good anti-inflammatory activity.
The foregoing shows and describes the general principles, essential features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (8)
1. Chromone-substituted 2-hydroxypyrrole derivatives, wherein the structural formula of the derivatives is shown in formula (I):
wherein n is 0 or 1;
r is hydrogen, fluorine, chlorine or methyl;
R1is hydrogen or fluorine;
R2is hydrogen, fluorine, chlorine or bromine;
EWG is benzoyl, p-methylbenzoyl, p-fluorobenzoyl, p-chlorobenzoyl or p-bromobenzoyl.
2. The method for synthesizing chromone-substituted 2-hydroxypyrrole derivatives according to claim 1, comprising the following steps:
adding a benzoylformaldehyde derivative, a coumarin derivative and heterocyclic ketene aminal into a solvent, stirring and reacting for 8-24 hours at the temperature of 70-120 ℃ to obtain a reaction liquid, cooling the reaction liquid to room temperature, and purifying to obtain a chromone-substituted 2-hydroxypyrrole derivative with the structure of formula (I); wherein the structural formula of the benzoyl formaldehyde derivative is shown as a formula (II), the structural formula of the coumarin derivative is shown as a formula (III), the structural formula of the heterocyclic ketene aminal is shown as a formula (IV),
in formula (II), R is hydrogen, fluorine, chlorine or methyl;
R1is hydrogen or fluorine;
in the formula (III), R2Hydrogen, fluorine, chlorine or bromine;
in formula (IV), n is 0 or 1;
EWG is benzoyl, p-methylbenzoyl, p-fluorobenzoyl, p-chlorobenzoyl or p-bromobenzoyl.
3. The method of synthesis as claimed in claim 2, wherein: the solvent is 1, 4-dioxane, ethanol, hydrogen peroxide or water.
4. The method of synthesis as claimed in claim 2, wherein: the molar ratio of the benzoyl formaldehyde derivative to the coumarin derivative to the heterocyclic ketene aminal is 1:1: 1.
5. The method of synthesis as claimed in claim 2, wherein: the purification treatment is column chromatography separation or recrystallization.
6. The method of synthesis of claim 5, wherein: the eluent for column chromatographic separation is dichloromethane/petroleum ether mixed solvent, ethyl acetate/petroleum ether mixed solvent or ethyl acetate/acetone mixed solvent.
7. The method of synthesis of claim 5, wherein: the solvent for recrystallization is a dichloromethane/petroleum ether mixed solvent or an ethyl acetate/petroleum ether mixed solvent.
8. Use of the chromone-substituted 2-hydroxypyrrole derivatives of claim 1 in the preparation of anti-inflammatory drugs.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910602021.3A CN110357891B (en) | 2019-07-05 | 2019-07-05 | Chromone-substituted 2-hydroxypyrrole derivative and synthesis method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910602021.3A CN110357891B (en) | 2019-07-05 | 2019-07-05 | Chromone-substituted 2-hydroxypyrrole derivative and synthesis method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110357891A CN110357891A (en) | 2019-10-22 |
CN110357891B true CN110357891B (en) | 2022-02-01 |
Family
ID=68218201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910602021.3A Expired - Fee Related CN110357891B (en) | 2019-07-05 | 2019-07-05 | Chromone-substituted 2-hydroxypyrrole derivative and synthesis method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110357891B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110938079B (en) * | 2019-12-31 | 2022-08-23 | 云南大学 | Spirooxoindole derivative and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101481345A (en) * | 2009-02-24 | 2009-07-15 | 云南大学 | Spirocyclic-beta-lactam 1-alkyl-2,7- dioxo-1- azaspiro [3.5]- nonane-5,8-diene-3-substituted carboxylic ether and preparation thereof |
CN106518885A (en) * | 2016-10-26 | 2017-03-22 | 云南大学 | 1,3-diazacyclopyridine quaternary ammonium salt compound, intermediate compound thereof as well as preparation methods and applications of compounds |
-
2019
- 2019-07-05 CN CN201910602021.3A patent/CN110357891B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101481345A (en) * | 2009-02-24 | 2009-07-15 | 云南大学 | Spirocyclic-beta-lactam 1-alkyl-2,7- dioxo-1- azaspiro [3.5]- nonane-5,8-diene-3-substituted carboxylic ether and preparation thereof |
CN106518885A (en) * | 2016-10-26 | 2017-03-22 | 云南大学 | 1,3-diazacyclopyridine quaternary ammonium salt compound, intermediate compound thereof as well as preparation methods and applications of compounds |
Non-Patent Citations (3)
Title |
---|
Multicomponent Cascade Reaction by Metal-Free Aerobic Oxidation for Synthesis of Highly Functionalized 2-Amino-4-coumarinyl-5-arylpyrroles;Quan-Xing Zi et al.;《J. Org. Chem.》;20191204;第85卷;第327-338页 * |
Synthesis, In-vivo and In-vitro Anti-inflammatory Evaluation of some Novel Coumarin Derivatives;Reem Al-Wabli et al.;《Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry》;20181231;第17卷(第2期);第115-124页 * |
杂环烯酮缩胺: 构筑分子多样性稠杂环化合物的合成先导分子;孔令斌等;《化学进展》;20181231;第30卷(第5期);第639-657页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110357891A (en) | 2019-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bhardwaj et al. | Pyrrole: a resourceful small molecule in key medicinal hetero-aromatics | |
CN113061138B (en) | Triazole [5,4-d ] pyrimidinone tricyclic compound, and preparation method and application thereof | |
Rashad et al. | Synthesis of some biologically active pyrazoles and C-nucleosides | |
CN111689904B (en) | Preparation method of triazole sulfur (selenium) ketone derivative | |
CN109134463B (en) | β -carboline type 5 phosphodiesterase inhibitor and preparation method and application thereof | |
Ben Mohamed et al. | An efficient synthetic access to substituted thiazolyl‐pyrazolyl‐chromene‐2‐ones from dehydroacetic acid and coumarin derivatives by a multicomponent approach | |
CN110357891B (en) | Chromone-substituted 2-hydroxypyrrole derivative and synthesis method and application thereof | |
CN112321604A (en) | Macrocyclic JAK2 inhibitor and application thereof | |
CN113105459A (en) | Triazolopyrimidine derivative and preparation method and application thereof | |
Tunel et al. | Synthesis, structural characterization, biological activity, and theoretical studies of some novel thioether‐bridged 2, 6‐disubstituted imidazothiadiazole analogues | |
CN116917287A (en) | Isoquinolinones and use thereof | |
Guillon et al. | Synthesis and preliminary in vitro evaluation of antimycobacterial activity of new pyrrolo [1, 2-a] quinoxaline-carboxylic acid hydrazide derivatives | |
CN110357892B (en) | Tetrahydropyrimidino [1,2-a ] indole derivative and synthesis method and application thereof | |
CN104725393A (en) | Bergenin derivative as well as preparation method and application thereof | |
Bhat et al. | Synthesis and characterization of novel Biginelli dihydropyrimidinone derivatives containing imidazole moiety | |
Andrade et al. | Trifluoromethyl β‐Enamino Diketones as Dual Substrates for the Synthesis of 5‐Benzoyl‐6‐(trifluoromethyl) pyrimidines and their Pyrimidin‐4 (3H)‐one Analogues | |
CN102060792B (en) | 2 '-amido chalcone azole compounds and pyrazoline thereof and cyclopropyl azole derivative, preparation method and purposes | |
Dotzauer et al. | 2, 4-Diamino-9H-pyrimido [4, 5-b] indol-5-ols: Synthesis, in vitro cytotoxic activity, and QSAR investigations | |
CN112010860B (en) | Benzyloxypyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof | |
CN114478549A (en) | Pyrazolo [3,4-d ] pyrrolo [1,2-a ] pyrimidone arylene derivative and application thereof | |
Tsyganov et al. | Arylglyoxal oximes as putative C-nucleophiles in eliminative nucleophilic substitution process | |
Basoglu Ozdemir et al. | Microwave‐Assisted Synthesis, Antioxidant, and Antimicrobial Evaluation of Piperazine‐Azole‐Fluoroquinolone Based 1, 2, 4‐Triazole Derivatives | |
CN112480129A (en) | Polycyclic spiroindoline compound containing guanidyl structural unit and preparation method and application thereof | |
CN111454232B (en) | 1,3, 4-thiadiazine compound and application thereof | |
Katrusiak et al. | One-step ring condensation of hydrazine derivatives and cyclic anhydrides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220201 |